GlassScriptPhysician profile
Erin Brooks
NPI 1396319935
$3,638.36
in general payments reported to CMS, 2019-2025
22 companies · $880 in 2025
The $880 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $588 · 2023: $696 · 2024: $1,097 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,672.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,149.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $499.88 | 2021-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $480.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $196.36 | 2022-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $173.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $164.59 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.36 | 2025 | Caplyta |
| Biosense Webster, INC. | $138.05 | 2022 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Medtronic, INC. | $93.75 | 2025 | Micra |
| Biohaven Pharmaceutical Holding Company LTD. | $78.61 | 2022 | |
| Phathom Pharmaceuticals, INC. | $64.76 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $60.01 | 2025 | Fanapt |
| Philips North America LLC | $57.52 | 2022 | |
| Exact Sciences Corporation | $47.61 | 2023-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $40.03 | 2023-2024 | Trintellix |
| Amgen INC. | $34.52 | 2022 | |
| Abbott Laboratories | $23.02 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $19.76 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $16.10 | 2022 | |
| Phadia US INC. | $15.52 | 2022 | |
| Irhythm Technologies, INC. | $15.01 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.